Recently, since several less toxic AR-targeted drugs became available and were approved by the Food and Drug Administration (FDA) for patients with prostate cancer, interest in evaluating the AR expression in breast cancer patients has been growing, especially in the triple-negative (ER, PR and HER2 negative) patients and in those patients that develop resistance to current breast cancer treatment possibilities. This evidence concerns the gene ESR1 and breast cancer.